Drilling Down Into the Data for Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 55.56M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For CYCN, the company currently has 117.03 million of cash on the books, which is offset by 0 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 3.25 million in total assets, balanced by 0 in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Cyclerion Therapeutics, Inc. saw 86766 in free cash flow last quarter, representing a quarterly net change in cash of 124760. Perhaps most importantly where cash movements are concerned, the company saw about 80052 in net operating cash flow.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 1.4 million in total revenues. That represents a quarterly year/year change in revenues of 1.00% in sequential terms, the CYCN saw sales decline by -0.16%.

But what about the bottom line? After all, that’s what really matters in the end. Cyclerion Therapeutics, Inc. is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.4 million, yielding a gross basic income of 29.41 million. For shareholders, given the total diluted outstanding shares of 27.78M, this means overall earnings per share of -27319000.